Last reviewed · How we verify

Universidad Peruana Cayetano Heredia — Portfolio Competitive Intelligence Brief

Universidad Peruana Cayetano Heredia pipeline: 1 marketed, 0 filed, 0 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
"Raltegravir" and "Zidovudine" "Raltegravir" and "Zidovudine" marketed Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitor) HIV integrase (raltegravir); HIV reverse transcriptase (zidovudine) Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Universidad Peruana Cayetano Heredia:

Cite this brief

Drug Landscape (2026). Universidad Peruana Cayetano Heredia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-peruana-cayetano-heredia. Accessed 2026-05-16.

Related